Zsofia Kote-Jarai

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. pmc Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease
    D Leongamornlert
    Division of Genetics and Epidemiology, The Institute of Cancer Research, London SW7 3RP, UK
    Br J Cancer 110:1663-72. 2014
  2. pmc Germline BRCA1 mutations increase prostate cancer risk
    D Leongamornlert
    Oncogenetics team, The Institute of Cancer Research, Sutton SM2 5NG, UK
    Br J Cancer 106:1697-701. 2012
  3. pmc Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers
    Z Kote-Jarai
    Translational Cancer Genetics Team, The Institute of Cancer Research, 15 Cotswold Rd, Sutton Surrey SM2 5NG, UK
    Br J Cancer 94:308-10. 2006
  4. pmc Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression
    Zsofia Kote-Jarai
    The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Hum Mol Genet 22:2520-8. 2013
  5. pmc BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
    Z Kote-Jarai
    Oncogenetics team, The Institute of Cancer Research, Sutton SM2 5NG, UK
    Br J Cancer 105:1230-4. 2011
  6. pmc Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript
    Z Kote-Jarai
    The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Hum Genet 129:687-94. 2011
  7. pmc Mutation analysis of the MSMB gene in familial prostate cancer
    Z Kote-Jarai
    Translational Cancer Genetics Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 102:414-8. 2010
  8. pmc A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer
    Z Kote-Jarai
    Translational Cancer Genetics Team, The Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 100:426-30. 2009
  9. ncbi request reprint BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial
    Zsofia Kote-Jarai
    Translational Cancer Genetics Team, Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Cancer Lett 247:259-65. 2007
  10. ncbi request reprint Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status
    Zsofia Kote-Jarai
    Translational Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
    Clin Cancer Res 10:958-63. 2004

Detail Information

Publications33

  1. pmc Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease
    D Leongamornlert
    Division of Genetics and Epidemiology, The Institute of Cancer Research, London SW7 3RP, UK
    Br J Cancer 110:1663-72. 2014
    ....
  2. pmc Germline BRCA1 mutations increase prostate cancer risk
    D Leongamornlert
    Oncogenetics team, The Institute of Cancer Research, Sutton SM2 5NG, UK
    Br J Cancer 106:1697-701. 2012
    ..We sought to evaluate the role of germline BRCA1 mutations in PrCa predisposition by performing a candidate gene study in a large UK population sample set...
  3. pmc Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers
    Z Kote-Jarai
    Translational Cancer Genetics Team, The Institute of Cancer Research, 15 Cotswold Rd, Sutton Surrey SM2 5NG, UK
    Br J Cancer 94:308-10. 2006
    ..Our finding has implications for treatment and screening of BRCA1 mutation carriers using modalities that involve irradiation...
  4. pmc Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression
    Zsofia Kote-Jarai
    The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Hum Mol Genet 22:2520-8. 2013
    ..Gene expression analysis of normal prostate tissue showed evidence that SNPs within one of these regions also associated with TERT expression, providing a potential mechanism for predisposition to disease...
  5. pmc BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
    Z Kote-Jarai
    Oncogenetics team, The Institute of Cancer Research, Sutton SM2 5NG, UK
    Br J Cancer 105:1230-4. 2011
    ..We previously estimated that about 2% of PrCa cases diagnosed ≤ 55 years harbour a BRCA2 mutation and PrCa among BRCA2 carriers has been shown to be more aggressive, with poorer survival...
  6. pmc Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript
    Z Kote-Jarai
    The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Hum Genet 129:687-94. 2011
    ..Using molecular dynamic simulation, we showed evidence that this variant has the potential to introduce alterations in the protein or affect RNA splicing. We propose that rs17632542 may directly influence PrCa risk...
  7. pmc Mutation analysis of the MSMB gene in familial prostate cancer
    Z Kote-Jarai
    Translational Cancer Genetics Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 102:414-8. 2010
    ..The MSMB protein is underexpressed in PrCa and it was previously proposed to be an independent marker for the recurrence of cancer after radical prostatectomy...
  8. pmc A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer
    Z Kote-Jarai
    Translational Cancer Genetics Team, The Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 100:426-30. 2009
    ....
  9. ncbi request reprint BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial
    Zsofia Kote-Jarai
    Translational Cancer Genetics Team, Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Cancer Lett 247:259-65. 2007
    ..03) in the cancers developing in tamoxifen-treated patients. These results suggest that tamoxifen is less likely to be effective at reducing breast cancers which are ER negative and also in some individuals at higher HR...
  10. ncbi request reprint Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status
    Zsofia Kote-Jarai
    Translational Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
    Clin Cancer Res 10:958-63. 2004
    ..The impact of the presence of a germ-line BRCA1 mutation on gene expression in normal breast fibroblasts after radiation-induced DNA damage has been investigated...
  11. ncbi request reprint Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage
    Zsofia Kote-Jarai
    Translational Cancer Genetics Team, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Clin Cancer Res 12:3896-901. 2006
    ..We aimed to establish if BRCA1/BRCA2 mutation carriers could be distinguished from noncarriers based on expression profiling of normal cells...
  12. ncbi request reprint Multiple newly identified loci associated with prostate cancer susceptibility
    Rosalind A Eeles
    The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
    Nat Genet 40:316-21. 2008
    ..7 x 10(-29)). We confirmed previous reports of common loci associated with prostate cancer at 8q24 and 17q. Moreover, we found that three of the newly identified loci contain candidate susceptibility genes: MSMB, LMTK2 and KLK3...
  13. ncbi request reprint Loss of heterozygosity at the BRCA1 and BRCA2 loci detected in ductal lavage fluid from BRCA gene mutation carriers and controls
    Imogen Locke
    The Institute of Cancer Research, London, UK
    Cancer Epidemiol Biomarkers Prev 15:1399-402. 2006
    ..Further studies are required to evaluate the specificity and predictive value of LOH in ductal lavage fluid for breast cancer development...
  14. pmc Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene
    Stephen M Edwards
    Translational Cancer Genetics Team, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Am J Hum Genet 72:1-12. 2003
    ..These results confirm that BRCA2 is a high-risk prostate-cancer-susceptibility gene and have potential implications for the management of early-onset prostate cancer, in both patients and their relatives...
  15. pmc Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays
    Sameer Jhavar
    Institute of Cancer Research, Male Urological Cancer Research Centre, Sutton, Surrey SM2 5NG, UK
    J Mol Diagn 10:50-7. 2008
    ..These studies demonstrate that expression analyses using exon arrays represent a valuable approach for detecting ETS gene translocation in prostate cancer, in parallel with analyses of gene expression profiles...
  16. pmc Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array
    Rosalind A Eeles
    The Institute of Cancer Research, Sutton, UK
    Nat Genet 45:385-91, 391e1-2. 2013
    ..7-fold higher risk than the average of the population being profiled. These results will facilitate population risk stratification for clinical studies...
  17. pmc Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study
    Zsofia Kote-Jarai
    The Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 43:785-91. 2011
    ..7 × 10(-24)). We also identified a SNP in TERT more strongly associated with PrCa than that previously reported. More than 40 PrCa susceptibility loci, explaining ∼25% of the familial risk in this disease, have now been identified...
  18. pmc Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls
    Imogen Locke
    Translational Cancer Genetics Team, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Breast Cancer Res 9:R20. 2007
    ....
  19. pmc Overexpression of RAD51 occurs in aggressive prostatic cancer
    Anita Mitra
    Translational Cancer Genetics Team, Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
    Histopathology 55:696-704. 2009
    ..To test the hypothesis that, in a matched series of prostatic cancers, either with or without BRCA1 or BRCA2 mutations, RAD51 protein expression is enhanced in association with BRCA mutation genotypes...
  20. pmc Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort
    Chee L Goh
    Oncogenetics team, The Institute of Cancer Research
    BJU Int 112:666-73. 2013
    ..This is the first study to date, which has investigated the potential prognostic role of SNP profiles in an AS cohort..
  21. pmc Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer
    Edward J Saunders
    The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    PLoS Genet 10:e1004129. 2014
    ....
  22. pmc Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium
    Zsofia Kote-Jarai
    Section of Cancer Genetics Team, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom
    Cancer Epidemiol Biomarkers Prev 17:2052-61. 2008
    ..This study provides strong confirmation of these susceptibility loci in multiple populations and shows that they make an important contribution to prostate cancer risk prediction...
  23. ncbi request reprint The genetic epidemiology of prostate cancer and its clinical implications
    Rosalind Eeles
    Oncogenetics team, Division of Cancer Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Nat Rev Urol 11:18-31. 2014
    ..However, risk modelling and clinical translational research are needed before we can translate risk profiles generated from these variants into use in the clinical setting for targeted screening and treatment. ..
  24. pmc Identification of new genetic risk factors for prostate cancer
    Michelle Guy
    Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
    Asian J Androl 11:49-55. 2009
    ..Follow-up validation studies, as well as studies to explore the psychological implications of genetic profile testing, will be vital prior to roll out into healthcare...
  25. pmc Identification of seven new prostate cancer susceptibility loci through a genome-wide association study
    Rosalind A Eeles
    The Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 41:1116-21. 2009
    ..In addition to replicating previous associations, we identified seven new prostate cancer susceptibility loci on chromosomes 2, 4, 8, 11 and 22 (with P = 1.6 x 10(-8) to P = 2.7 x 10(-33))...
  26. pmc Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14
    Elise Ruark
    Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, UK
    Nat Genet 45:686-9. 2013
    ..3, is required for the regulation of germ cell development. Furthermore, PITX1, at 5q31.1, regulates TERT expression and is the third TGCT-associated locus implicated in telomerase regulation...
  27. pmc Telomere length shows no association with BRCA1 and BRCA2 mutation status
    Emma Killick
    Division of Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom Oncogentics, Institute of Cancer Research, Surrey, United Kingdom
    PLoS ONE 9:e86659. 2014
    ....
  28. ncbi request reprint Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer
    Sameer Jhavar
    Institute of Cancer Research, Male Urological Cancer Research Centre, Sutton, Surrey, UK
    BJU Int 103:1256-69. 2009
    ....
  29. pmc Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men
    Emma Killick
    Institute of Cancer Research, Sutton, Surrey, UK
    Sci Rep 3:2059. 2013
    ..Urinary EN2 may be useful as a non-invasive early biomarker for prostate cancer detection in genetically high-risk individuals. ..
  30. ncbi request reprint Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia
    Martin Yuille
    Academic Department of Haematology and Cytogenetics, and the Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Blood 99:4216-8. 2002
    ..04). The risk of CLL associated with possession of all 3 "high-risk" genotypes was increased 2.8-fold (OR = 2.8, 95% confidence interval: 1.1-6.9). Our findings suggest that heritable GST status may influence the risk of developing CLL...
  31. ncbi request reprint Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility
    Julian Barwell
    Clinical Genetics, St George s University of London, United Kingdom
    Int J Cancer 121:1631-6. 2007
    ..Our results show a demonstrable impairment in irradiation induced DNA repair in women with heterozygous germline BRCA1 and BRCA2 mutations prior to being diagnosed with breast cancer...
  32. ncbi request reprint Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers
    Luna Kadouri
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, Israel
    Int J Cancer 108:399-403. 2004
    ..Longer repeat length correlates with elevated risk, whereas in carriers of a shorter AIB1 allele BC risk was reduced. The AIB1 polyglutamine length did not affect BC risk among BRCA2 mutation carriers...
  33. pmc Multiple loci with different cancer specificities within the 8q24 gene desert
    Maya Ghoussaini
    Cancer Research UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, CB1 8RN, Cambridge, UK
    J Natl Cancer Inst 100:962-6. 2008
    ..We conclude that there are at least five separate functional variants in this region...